Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer. All of Odyssey’s…